Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MenACWY-CRM197 in Healthy Infants and Toddlers
NCT00667602Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Primary completion
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal meningitis (3 arms), sponsored by Novartis. Primary endpoint: Percentages of Subjects With Serum Bactericidal Titer >= 1:8 Against N.Meningitidis Serogroup C. Started Mar 2008; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT00667602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667602.